Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance

Increasing azithromycin treatment failure in sexually transmitted Mycoplasma genitalium infection, is linked to macrolide resistance and second-line treatment relies on the fluoroquinolone, moxifloxacin. We recently detected fluoroquinolone and macrolide resistance-associated mutations in 15% and 43%, respectively, of 143 initial M. genitalium PCR-positive specimens. For a subset of 33 Western Sydney Sexual Health Centre patients, clinical information and results of sequence analysis of M. genitalium macrolide and fluoroquinolone target genes – the 23S rRNA gene, and parC and gyrA, respectively – were used to examine whether mutations were associated with treatment failure. Macrolide resistance-associated mutations correlated with microbiological (p = 0.013) and clinical (p = 0.024) treatment failure, and fluoroquinolone resistance-associated mutations with microbiological moxifloxacin treatment failure (p = 0.005). We describe the first reported cases of clinical and microbiological moxifloxacin treatment failure. Failure of first- and second-line antibiotic treatment of M. genitalium infection is occurring and likely to increase with current treatment strategies.

[1]  G. Gilbert,et al.  Fluoroquinolone and Macrolide Resistance-Associated Mutations in Mycoplasma genitalium , 2013, Journal of Clinical Microbiology.

[2]  R. Hayes,et al.  Natural history of Mycoplasma genitalium Infection in a Cohort of Female Sex Workers in Kampala, Uganda , 2013, Sexually transmitted diseases.

[3]  Navneet R. Hakhu,et al.  Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Garland,et al.  Transmission and Selection of Macrolide Resistant Mycoplasma genitalium Infections Detected by Rapid High Resolution Melt Analysis , 2012, PloS one.

[5]  D. Taylor-Robinson,et al.  Mycoplasma genitalium: from Chrysalis to Multicolored Butterfly , 2011, Clinical Microbiology Reviews.

[6]  S. Garland,et al.  'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women.' , 2011, BMC infectious diseases.

[7]  島田 康司,et al.  Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance , 2011 .

[8]  V. Sintchenko,et al.  Ureaplasma urealyticum is significantly associated with non-gonococcal urethritis in heterosexual Sydney men , 2010, International journal of STD & AIDS.

[9]  H. Moi,et al.  Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study , 2008, International journal of STD & AIDS.

[10]  J. Jensen,et al.  Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial , 2007, Sexually Transmitted Infections.

[11]  S. Garland,et al.  Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. , 2006, The Journal of infectious diseases.

[12]  J. Jensen,et al.  Use of TaqMan 5′ Nuclease Real-Time PCR for Quantitative Detection of Mycoplasma genitalium DNA in Males with and without Urethritis Who Were Attendees at a Sexually Transmitted Disease Clinic , 2004, Journal of Clinical Microbiology.